President Joe Biden has officially signed into law legislation that includes provisions to fund psychedelic studies.
Psilocybin (top left), MDMA (top right), ibogaine (bottom left) and DMT (bottom right).
Last week both the Senate and House of Representatives gave approval to the 2024 National Defense Authorization Act, including provisions that would put millions of dollars into funding the potential medical and therapeutic use of psychedelic substances including psilocybin (“magic mushrooms”) and MDMA (often referred to as ecstasy). President Biden today signed the bill into law.
The psychedelic provisions were introduced by Representative Morgan Littrell (R). Once in effect, they will require the Department of Defense to establish a process for military members who have post traumatic stress disorder (PTSD) or traumatic brain injury to take part in clinical psychedelic trials. In addition to psilocybin and MDMA, the trials could include ibogaine and/or DMT.
The law requires the Department of Defense to initiate the process to begin the trials within 180 days of the bill being passed, and it would allocate $10 million to the program.
“I was honored to see several of my amendments and priorities accepted into the final version of the bill, including clinical trials on psychedelic therapy to treat PTSD, support for TBI research, and other key provisions that will ensure a safer, stronger United States,” said Rep. Luttrell. “This legislation will ensure America can face security challenges with lethality and readiness.”
